The Systemic Lupus International Collaborating Clinics–ACR Damage Index (SDI) has been widely used for 25 years. This index, however, has its limitations, providing a rationale for a global initiative to create a revised, updated SDI to capture organ damage across the age-spectrum.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany
BMC Rheumatology Open Access 17 May 2024
-
Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study
Clinical Rheumatology Open Access 10 January 2024
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
27 April 2021
A Correction to this paper has been published: https://doi.org/10.1038/s41584-021-00620-3
References
Strand, V. et al. Endpoints: consensus recommendations from OMERACT IV. Lupus 9, 322–327 (2000).
Gladman, D. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 39, 363–369 (1996).
Parker, B. & Bruce, I. N. in Dubois’ Lupus Erythematosus and Related Syndromes (eds D. J. Wallace & Hahn, B. H.) Ch. 49, 614–630 (2019).
Barber, M. R. W. et al. Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach. Arthritis Care Res. (Hoboken) 72, 1800–1808 (2019).
Van Vollenhoven, R. F. et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann. Rheum. Dis. 73, 958–967 (2014).
Mahieu, M. A., Strand, V., Simon, L. S., Lipsky, P. E. & Ramsey-Goldman, R. A critical review of clinical trials in systemic lupus erythematosus. Lupus 25, 1122–1140 (2016).
Touma, Z., Urowitz, M. B., Ibanez, D. & Gladman, D. D. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J. Rheumatol. 41, 688–697 (2014).
Holland, M. J. et al. Measuring disease damage and its severity in childhood-onset systemic lupus erythematosus. Arthritis Care Res. 70, 1621–1629 (2018).
Sutton, E. J., Davidson, J. E. & Bruce, I. N. The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin. Arthritis Rheum. 43, 352–361 (2013).
Acknowledgements
The authors acknowledge funding support from the Lupus Foundation of America and the ACR. INB is a National Institute for Health Research (NIHR) Senior Investigator and is funded by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.R.W.B has received consulting fees from Janssen and Sanofi Genzyme. S.R.J. has received consulting fees from Boehringer Ingelheim and Ikaria. D.D.G. has received grants from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer and UCB, and consulting fees from AbbVie, Amgen, BMS, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer and UCB. A.E.C. has received consulting fees from AstraZeneca, Exagen Diagnostics, BristolMyersSquibb and GSK. I.N.B. has received grant support from Genzyme/Sanofi, GSK, Roche and UCB; consulting fees from AstraZeneca, Eli Lilly, GSK, Merck Serono, UCB and ILTOO; and was a speaker for AstraZeneca, GSK and UCB.
Rights and permissions
About this article
Cite this article
Barber, M.R.W., Johnson, S.R., Gladman, D.D. et al. Evolving concepts in systemic lupus erythematosus damage assessment. Nat Rev Rheumatol 17, 307–308 (2021). https://doi.org/10.1038/s41584-021-00611-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-021-00611-4
This article is cited by
-
Clinical and economic burden of organ damage among patients with systemic lupus erythematosus in a real-world setting in Germany
BMC Rheumatology (2024)
-
Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study
Clinical Rheumatology (2024)